
Artera mHSPC expansion puts AI to work in first‑line care
On June 4, 2026, Artera said it had expanded its validated multimodal AI platform to metastatic hormone‑sensitive prostate cancer (mHSPC), introducing what it calls the first digital pathology‑based test to provide individual risk estimates for treatment planning in that setting. According to Artera’s site, the model blends AI analysis of biopsy slides with clinical variables […]







